Apaziquone
Apaziquone
Apaziquone (pronunciation: /əˈpæzɪkwɒn/) is a bioreductive alkylating agent used in the treatment of non-muscle invasive bladder cancer (NMIBC). It is also known by its trade name, Qapzola.
Etymology
The name "Apaziquone" is derived from the chemical structure of the drug, which belongs to the class of quinones. The prefix "Apa-" is an abbreviation of "alkylating agent", and "-ziquone" is a modification of "quinone".
Mechanism of Action
Apaziquone is activated in the hypoxic environment of cancer cells, where it forms cytotoxic species that can alkylate DNA and proteins, leading to cell death. This mechanism of action is similar to other bioreductive alkylating agents, such as Mitomycin C and Etoposide.
Clinical Use
Apaziquone is used for the treatment of non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumors (TURBT). It is instilled into the bladder through a catheter, where it can directly act on the cancer cells.
Related Terms
- Bioreductive alkylating agent
- Non-muscle invasive bladder cancer (NMIBC)
- Transurethral resection of bladder tumors (TURBT)
- Mitomycin C
- Etoposide
See Also
External links
- Medical encyclopedia article on Apaziquone
- Wikipedia's article - Apaziquone
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski